S&P 500   3,330.71 (+0.16%)
DOW   29,279.22 (+0.41%)
QQQ   225.63 (+0.46%)
AAPL   321.08 (+0.58%)
FB   221.53 (+0.81%)
MSFT   167.05 (+0.20%)
GOOGL   1,493.05 (+0.56%)
AMZN   1,890.00 (+0.29%)
CGC   24.63 (+0.29%)
NVDA   257.31 (+1.76%)
BABA   218.35 (-0.36%)
MU   59.92 (+1.22%)
GE   11.75 (-0.25%)
TSLA   567.12 (-0.89%)
AMD   52.46 (+1.45%)
T   38.56 (-0.18%)
ACB   2.07 (+0.00%)
F   9.11 (-0.44%)
NFLX   346.47 (-0.90%)
PRI   125.55 (+0.00%)
BAC   34.03 (-0.26%)
DIS   140.82 (-0.97%)
GILD   63.82 (-0.19%)
S&P 500   3,330.71 (+0.16%)
DOW   29,279.22 (+0.41%)
QQQ   225.63 (+0.46%)
AAPL   321.08 (+0.58%)
FB   221.53 (+0.81%)
MSFT   167.05 (+0.20%)
GOOGL   1,493.05 (+0.56%)
AMZN   1,890.00 (+0.29%)
CGC   24.63 (+0.29%)
NVDA   257.31 (+1.76%)
BABA   218.35 (-0.36%)
MU   59.92 (+1.22%)
GE   11.75 (-0.25%)
TSLA   567.12 (-0.89%)
AMD   52.46 (+1.45%)
T   38.56 (-0.18%)
ACB   2.07 (+0.00%)
F   9.11 (-0.44%)
NFLX   346.47 (-0.90%)
PRI   125.55 (+0.00%)
BAC   34.03 (-0.26%)
DIS   140.82 (-0.97%)
GILD   63.82 (-0.19%)
S&P 500   3,330.71 (+0.16%)
DOW   29,279.22 (+0.41%)
QQQ   225.63 (+0.46%)
AAPL   321.08 (+0.58%)
FB   221.53 (+0.81%)
MSFT   167.05 (+0.20%)
GOOGL   1,493.05 (+0.56%)
AMZN   1,890.00 (+0.29%)
CGC   24.63 (+0.29%)
NVDA   257.31 (+1.76%)
BABA   218.35 (-0.36%)
MU   59.92 (+1.22%)
GE   11.75 (-0.25%)
TSLA   567.12 (-0.89%)
AMD   52.46 (+1.45%)
T   38.56 (-0.18%)
ACB   2.07 (+0.00%)
F   9.11 (-0.44%)
NFLX   346.47 (-0.90%)
PRI   125.55 (+0.00%)
BAC   34.03 (-0.26%)
DIS   140.82 (-0.97%)
GILD   63.82 (-0.19%)
S&P 500   3,330.71 (+0.16%)
DOW   29,279.22 (+0.41%)
QQQ   225.63 (+0.46%)
AAPL   321.08 (+0.58%)
FB   221.53 (+0.81%)
MSFT   167.05 (+0.20%)
GOOGL   1,493.05 (+0.56%)
AMZN   1,890.00 (+0.29%)
CGC   24.63 (+0.29%)
NVDA   257.31 (+1.76%)
BABA   218.35 (-0.36%)
MU   59.92 (+1.22%)
GE   11.75 (-0.25%)
TSLA   567.12 (-0.89%)
AMD   52.46 (+1.45%)
T   38.56 (-0.18%)
ACB   2.07 (+0.00%)
F   9.11 (-0.44%)
NFLX   346.47 (-0.90%)
PRI   125.55 (+0.00%)
BAC   34.03 (-0.26%)
DIS   140.82 (-0.97%)
GILD   63.82 (-0.19%)
Log in
(Ad)
CNN calls 5G "the lifeblood of the new economy." If you don't invest now, you'll regret it later.

OTCMKTS:CTDH - CTD Stock Price, Forecast & News

$0.19
-0.01 (-5.00 %)
(As of 01/24/2020 09:37 AM ET)
Today's Range
$0.18
Now: $0.19
$0.20
50-Day Range
$0.19
MA: $0.26
$0.34
52-Week Range
$0.13
Now: $0.19
$0.84
Volume246,000 shs
Average Volume147,977 shs
Market Capitalization$23.12 million
P/E RatioN/A
Dividend YieldN/A
Beta0.43
CTD Holdings, Inc., a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. CTD Holdings, Inc. was founded in 1990 and is based in Gainesville, Florida.

Industry, Sector and Symbol

Industry Industrial organic chemicals
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CTDH
CUSIPN/A
Phone386-418-8060

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.01 million
Book Value$0.01 per share

Profitability

Net Income$-4,260,000.00
Net Margins-614.02%

Miscellaneous

Employees5
Market Cap$23.12 million
Next Earnings Date3/20/2020 (Estimated)
OptionableNot Optionable

Receive CTDH News and Ratings via Email

Sign-up to receive the latest news and ratings for CTDH and its competitors with MarketBeat's FREE daily newsletter.


CTD (OTCMKTS:CTDH) Frequently Asked Questions

What is CTD's stock symbol?

CTD trades on the OTCMKTS under the ticker symbol "CTDH."

How were CTD's earnings last quarter?

CTD Holdings, Inc. (OTCMKTS:CTDH) released its earnings results on Thursday, November, 14th. The biotechnology company reported ($0.01) earnings per share for the quarter. The biotechnology company had revenue of $0.29 million for the quarter. CTD had a negative net margin of 614.02% and a negative return on equity of 293.55%. View CTD's Earnings History.

When is CTD's next earnings date?

CTD is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for CTD.

Has CTD been receiving favorable news coverage?

Press coverage about CTDH stock has trended very positive on Friday, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CTD earned a news sentiment score of 3.9 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for CTD.

Who are some of CTD's key competitors?

What other stocks do shareholders of CTD own?

Who are CTD's key executives?

CTD's management team includes the folowing people:
  • Mr. N. Scott Fine, Chairman & CEO (Age 62)
  • Dr. Jeffrey L. Tate, COO & Director (Age 61)
  • Dr. Sharon H. Hrynkow, Chief Scientific Officer, SVP of Medical Affairs & Member of Scientific Advisory Board (Age 59)
  • Mr. George L. Fails, Exec. VP and Operations Mang. (Age 74)

How do I buy shares of CTD?

Shares of CTDH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is CTD's stock price today?

One share of CTDH stock can currently be purchased for approximately $0.19.

How big of a company is CTD?

CTD has a market capitalization of $23.12 million and generates $1.01 million in revenue each year. CTD employs 5 workers across the globe.View Additional Information About CTD.

What is CTD's official website?

The official website for CTD is http://www.ctd-holdings.com/.

How can I contact CTD?

CTD's mailing address is 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653. The biotechnology company can be reached via phone at 386-418-8060.


MarketBeat Community Rating for CTD (OTCMKTS CTDH)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  123
MarketBeat's community ratings are surveys of what our community members think about CTD and other stocks. Vote "Outperform" if you believe CTDH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTDH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2020 by MarketBeat.com Staff

Featured Article: Stock Portfolio Tracker

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel